GHRH (1-44) — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

GHRH (1-44)

Also known as: Growth Hormone-Releasing Hormone, hGHRH (1-44), hGHRH(1-44)NH2, Somatocrinin, GRF (1-44), Growth Hormone-Releasing Factor, GHRF, hGRF (1-44)

Endogenous hypothalamic neuropeptide / GH secretagogue — full-length 44-amino-acid growth hormone-releasing hormone

Research chemicalLast updated: October 19, 2026Based on 9 peer-reviewed studies

What it is

GHRH (1-44) is the full-length form of the natural hormone that drives growth hormone release from the pituitary, used as a research tool to study the growth hormone axis and metabolic disease. Shorter synthetic versions (sermorelin, tesamorelin) are approved; the full-length natural form is not. Not FDA-approved in this form.

The scientific side

GHRH(1-44) is the full-length endogenous 44-amino-acid neuropeptide produced by neurons of the hypothalamic arcuate nucleus that drives the somatotroph axis. It is the canonical physiological stimulus for pulsatile growth hormone (GH) release from anterior pituitary somatotrophs. The shorter synthetic fragment GHRH(1-29) (sermorelin) retains full agonist activity; this page covers the native 44-aa form (see also our page on GHRH (1-29) for the clinical analog). GHRH binds the pituitary-type GHRH receptor (GHRHR), a Gs-coupled GPCR expressed on somatotrophs and, via splice variant SV1, on numerous extrapituitary and tumor tissues. Receptor engagement activates Gα(s), elevates intracellular cAMP, and engages PKA and downstream cascades including PI3K/AKT, ERK1/2, and CREB-mediated transcription of GH gene targets. In somatotrophs, the cAMP/PKA cascade opens voltage-gated calcium channels, triggering GH secretion vesicle fusion. Beyond the pituitary, GHRH exerts direct extrapituitary actions. In cardiac tissue, GHRH(1-44)NH₂ acts through Gα(s)/cAMP/PKA signaling to block the Gq/PLC-β/PKC-ε/calcineurin hypertrophy cascade in cardiomyocytes, positioning it as an endogenous antihypertrophic regulator. In neural tissues, GHRH activates cAMP/PKA/CREB and PI3K/Akt pathways, enhances neuronal survival, reduces tau phosphorylation, and suppresses NF-κB-mediated neuroinflammation. In pancreatic beta-cells, GHRH and its analogs enhance cell survival, supporting beta-cell mass preservation in diabetes models. GH secretion is modulated by the interplay of GHRH (stimulatory), somatostatin (inhibitory), and ghrelin (synergistic with GHRH), with additional modulation by leptin, nesfatin, klotho, thyroid hormones, sex steroids, and metabolic substrates such as glucose and free fatty acids. Critically, pulsatile GH release depends on the alternating phases of GHRH stimulation and somatostatin withdrawal rather than continuous GHRH exposure. The GHRH(1-44) full-length form and GHRH(1-29) analogs such as tesamorelin have been used in research to probe this axis; tesamorelin at 2 mg SC daily for two weeks significantly increased overnight mean GH pulses (p=0.004) and IGF-I by ~181 µg/L (p<0.0001) without impairing insulin sensitivity in healthy men. Note: for the synthetic 29-residue research fragment commonly used in community protocols (Sermorelin), see /peptides/ghrh-1-29.

Class: Endogenous hypothalamic neuropeptide / GH secretagogue — full-length 44-amino-acid growth hormone-releasing hormone

Administration & storage

Administration
Subcutaneous injection — used in human tesamorelin analog study (PMID: 20943777)Intravenous bolus — used in animal study in mithuns (PMID: 16843461)Subcutaneous injection — MR-409 GHRH agonist in 5xFAD mouse model (PMID: 41946684)
Storage
No storage data for native GHRH(1-44) described in reviewed abstracts. Standard peptide storage guidance: lyophilized form at -20°C; reconstituted solutions at 4°C short-term or -80°C for longer storage.
Cautions
No human safety data exists specifically for native GHRH(1-44). Safety data in humans are derived from GHRH analog studies (sermorelin, tesamorelin) rather than the full-length native form.,GHRH agonist MR-409 in 5xFAD mice at therapeutic doses did not alter systemic GH or IGF-1 levels, suggesting potential for dissociation of central and peripheral effects, but translational relevance to humans is unknown.,Synthetic GHRH analogs with modifications have been identified in black-market performance-enhancing products, raising concerns about impurity and undisclosed modifications.,Potential for promoting growth of GHRHR-expressing tumors — antagonists rather than agonists are being studied for cancer indications.

Legal & regulatory status

US FDA

Not approved by the US FDA as a therapeutic drug. The native 44-amino-acid form is a research tool compound. The synthetic truncated fragment GHRH(1-29) (sermorelin) is FDA-approved; tesamorelin (a GHRH analog) is…

WADA

Not stated in reviewed literature as explicitly prohibited. GHRH analogs (including sermorelin and tesamorelin) are listed under S2 Peptide Hormones as GH secretagogues on the WADA Prohibited List; the full-length…

Health Canada

Not stated in reviewed literature as an approved therapeutic — requires manual verification. Synthetic GHRH analogs have been identified in confiscated performance-enhancing drug products, indicating black-market use.